ACICLOVIR-RESISTANT HERPES SIMPLEX VIRUS IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT: A CASE SERIES (EBMT 2026) - Feb 7, 2026 - Abstract #P160; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "All patients were treated with second-line antivirals (foscarnet and/or cidofovir), and three patients were treated with third-line antivirals (pritelivir). Aciclovir-resistant HSV infection in pediatric HSCT recipients is associated with high morbidity and mortality, limited therapeutic options, and significant treatment-related toxicity. Early recognition, resistance testing, timely initiation of second-line therapy and weaning of immunosuppression are critical for disease control. Emerging therapies, such as helicase-primase inhibitors and adoptive T-cell therapy, hold promise but remain limited by access and pediatric data."
Clinical • Bone Marrow Transplantation • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Herpes Simplex • Immunology • Infectious Disease • Inflammation • Keratitis • Leukemia • Myelodysplastic Syndrome • Ocular Inflammation • Ophthalmology • Pediatrics • Pneumonia • Primary Immunodeficiency • Respiratory Diseases • Sickle Cell Disease • Transplantation • Transplantation Associated Thrombotic Microangiopathy
|
|
Jenna Nunn1; Ahmed Ahmed1; Srividhya Senthil1; Oana Mirci-Danicar1; Denise Bonney1; Claire Horgan1; Omima Mustafa1; Robert Wynn1; Malcolm Guiver1; Ramya Nataraj1
|